Evaluation of the in vivo antithrombotic, anticoagulant and fibrinolytic activities of Lumbricus rubellus earthworm powder

被引:11
作者
Hahn, BS [1 ]
Jo, YY [1 ]
Yang, KY [1 ]
Wu, SJ [1 ]
Pyo, MK [1 ]
YunChoi, HS [1 ]
Kim, YS [1 ]
机构
[1] SEOUL NATL UNIV,INST NAT PROD RES,SEOUL 110460,SOUTH KOREA
关键词
Lumbricus rubellus earthworm powder; antiplatelet activity; anticoagulant activity; fibrinolytic activity; oral administration;
D O I
10.1007/BF02974036
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
A saline suspension of Lumbricus rubellus earthworm powder (EWP) was administered to rats (1 g/kg/day) orally for 15 days to evaluate an oral effectiveness for thrombotic disorders. Blood was drawn at 2-day interval after the administration. Several parameters for antithrombotic, anticoagulant and fibrinolytic activities were measured, including platelet aggregation, clotting time, plasmin activity and the levels of FDP (fibrin/fibrinogen degradation products), D-dimer, and t-PA antigen. It did not affect platelet aggregation induced by ADP and collagen but anticoagulant activity (aPTT and TT) was gradually increased to two-folds for the first 5 days of administration and back to normal. Fibrinolytic activity of euglobulin fraction was highest on the 11th day after the administration. The level of FDP was elevated to be comparable to the positve control (5-10 mu g/ml) after 9-day treatment. Oral administration of the EWP could also reduce the formation of venous thrombus induced with viper venom. Complete blood count (CBC) profiles were within normal ranges except for a slight increase in white blood cells after the oral administration for 15 days. These results suggested that the EWP may be valuable for the prevention and/or treatment of thrombotic diseases.
引用
收藏
页码:17 / 23
页数:7
相关论文
共 17 条
[1]
EFFECTS OF POLICOSANOL ON PLATELET-AGGREGATION IN RATS [J].
ARRUZAZABALA, ML ;
CARBAJAL, D ;
MAS, R ;
GARCIA, M ;
FRAGA, V .
THROMBOSIS RESEARCH, 1993, 69 (03) :321-327
[2]
THE FIBRIN PLATE METHOD FOR ESTIMATING FIBRINOLYTIC ACTIVITY [J].
ASTRUP, T ;
MULLERTZ, S .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1952, 40 (02) :346-351
[3]
DIMINNO G, 1983, J PHARMACOL EXP THER, V225, P57
[4]
A MODIFIED STASIS THROMBOSIS MODEL TO STUDY THE ANTITHROMBOTIC ACTIONS OF HEPARIN AND ITS FRACTIONS [J].
FAREED, J ;
WALENGA, JM ;
KUMAR, A ;
ROCK, A .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1985, 11 (02) :155-175
[5]
THE EFFECT OF ULTRA-LOW-DOSE HEPARIN IN EXPERIMENTAL VENOUS THROMBOSIS [J].
HLADOVEC, J .
THROMBOSIS RESEARCH, 1984, 36 (01) :83-85
[6]
HONG SY, 1991, KOR J INT MED, V40, P77
[7]
KIM JK, 1995, TRADITIONAL DRUGS E, P415
[8]
MIHARA H, 1992, ASIAN J TROP MED P S, V23, P531
[9]
MIHARA H, 1991, JAP J PHYSL, V461, P461
[10]
MIHARA H, 1993, THROMB HAEMOSTASIS, V50, P139